Our work further suggest that in part by restoring MTSS1 expression to suppress cancer cell growth, proliferation and metastasis, β-TRCP inhibitors or CKI inhibitors may be beneficial in treating various types of human cancers, particularly the metastatic cancers that are associated with poor survival rates. This evidence concerns the gene CHKA and metastatic malignant neoplasm.